> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Senate Report Warns on China's Threat to U.S. Pharma Innovation
- URL: https://www.fdaweb.com/hill-report-warns-on-chinas-threat-to-u-s-pharma-innovation/
- Published: 2026-11-19T16:46:08.000Z
- Updated: 2026-11-19T17:33:49.000Z
- Author: David McFarland
- Tags: Drugs

A congressional advisory commission is warning that China's expanding role in pharmaceutical discovery, development and licensing threatens the U.S.’s lead in drug innovation and could eventually leave American patients vulnerable to disruptions in access to critical medicines.

In an [11/18 report](https://www.biotech.senate.gov/wp-content/uploads/2026/11/NSCEB-Innovated-in-China-11.18.26.pdf?ref=fdaweb.com), the National Security Commission on Emerging Biotechnology (NSCEB) said Chinese biotech companies are increasingly attracting U.S. pharmaceutical investment while acquiring the capital, expertise and regulatory knowledge needed to compete directly in American and international markets.

The commission examined 57 licensing agreements involving the 15 largest pharmaceutical companies operating in the U.S. and 42 Chinese biotechnology companies between 1/2023 and 10/2026\. It found that upfront deal values are rising and agreements increasingly involve drug candidates supported only by preclinical data. According to the commission, the trend indicates that multinational drugmakers are becoming more willing to rely on Chinese companies for early-stage drug discovery and development.

The report also identified a progression from single-product licensing agreements to broader collaborations involving multiple drug candidates, discovery platforms and joint commercialization arrangements.

Such partnerships can provide Chinese companies with knowledge of U.S. drug development, commercialization and regulatory practices, potentially strengthening their ability to enter the American market independently, the commission warned.

The commission expressed particular concern about emerging "NewCo" arrangements in which U.S. investors establish companies to develop and commercialize drug candidates licensed from Chinese biotechnology firms. These transactions can provide Chinese companies with upfront payments, milestone compensation, equity interests and future royalties.

The commission argued that these arrangements could redirect American investment toward Chinese pharmaceutical innovation rather than domestic research and development.

The report also highlighted China's 9/2026 pharmaceutical industry plan, which seeks to increase first-in-class drug development, pharmaceutical revenues and global sales by 2030\. The Chinese strategy identifies more than 300 technical methods and products for development across the pharmaceutical supply chain.

The commission also warned that a Chinese proposal last month to restrict exports of certain advanced biopharmaceutical technologies, including proprietary drug discovery platforms, could eventually give Beijing greater leverage over international pharmaceutical development. Those restrictions have not been finalized.

The NSCEB acknowledged that Chinese partnerships offer multinational pharmaceutical companies opportunities to reduce development costs and share financial risks. However, it warned that growing dependence on Chinese innovation could create vulnerabilities similar to those already identified in pharmaceutical manufacturing and raw-material supply chains.

The commission characterized the Treasury Department's recent proposed restrictions on outbound U.S. investment in certain Chinese biotechnology activities as a prudent step but said additional federal action is needed to strengthen domestic pharmaceutical innovation.